<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273932</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003688</org_study_id>
    <nct_id>NCT04273932</nct_id>
  </id_info>
  <brief_title>Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.</brief_title>
  <official_title>Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if one of three low doses of lithium therapy for 6 months can
      engage one or more blood-based therapeutic targets implicated in Parkinson's disease (PD)
      pathophysiology. Results of this study will help to determine if lithium therapy is
      worthwhile to further investigate as a potential disease-modifying therapy in PD, the optimal
      dose to study and the optimal PD subgroup most likely to benefit from lithium therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lithium belongs to a class of kinase-targeting therapies, including the diabetes medication
      exenatide and the cancer medication nilotinib, that have demonstrated promise as
      disease-modifying therapies for Parkinson's disease (PD). Exenatide was recently shown to
      engage protein kinase B (Akt) and provide significant symptomatic and possible
      disease-modifying benefit in PD in a phase 2 randomized controlled trial (RCT). Nilotinib
      engages c-Abelson kinase (c-Abl) and its disease-modifying effects are currently being
      investigated in two, phase 2 PD RCTs. Lithium targets Akt, glycogen synthase kinase-3 beta
      (GSK-3B, a downstream target of Akt) and cyclin-dependent kinase 5 (cdk5, a downstream target
      of c-Abl) in manners that recapitulate those of exenatide and nilotinib. Also, lithium
      inhibits inositol monophosphate leading to enhanced autophagy and reduced intracellular
      levels of alpha-synuclein (a-synuclein), which is believed to be a primary mediator of the
      progressive neurodegeneration in PD. In addition to a-synuclein, genome-wide association
      studies (GWAS) have implicated oligomeric tau in the pathogenesis of PD. Pathological
      mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of a
      late-onset parkinsonism that is clinically indistinguishable from sporadic PD and very
      similar pathologically. Pathological LRRK2 mutations affect the activities of Akt, GSK-3B and
      cdk5 to greatly increase the formation of phosphorylated tau (p-tau) - the precursor to tau
      oligomer formation - and decrease the activity of the transcriptional cofactor B-catenin -
      which mediates the transcription of neuronal survival genes implicated in PD such as nuclear
      receptor related 1 (Nurr1). Through its ability to inhibit GSK-3B, lithium can enhance
      B-catenin-mediated activity and Nurr1 expression. Lithium was also effective in several PD
      animal models. Finally, both clinical trial and epidemiologic data suggest that lithium
      exposures of even &lt;1mg a day may provide significant disease-modifying effects in
      neurodegenerative diseases including PD.

      The investigators propose to assess the effects of 3 lithium dosages for 6 months on the
      above targets measured in blood in a randomized, parallel design, proof of concept clinical
      trial among 18 PD patients. In addition, 2 PD patients will serve as controls and not receive
      lithium therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel group, open-label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma alpha-synuclein assessed by ultra-sensitive, immunomagnetic reduction assay (MagQu, LLC, Surprise, AZ).</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral blood mononuclear cell (PBMC) Nurr1 mRNA levels by real-time polymerase chain reaction.</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PBMC phosphorylated (p) and total (t) levels of pSerine9 and t-glycogen synthase kinase-3B</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma brain-derived neurotrophic factor (BDNF).</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PBMC pThreonine308 and t-protein kinase B (Akt).</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough, steady-state plasma lithium levels by ICP/MS</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient tolerability</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Assessed by patient reported adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III (Motor Examination) and question 1.11 (Constipation Problems) in the &quot;on&quot; state</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 0-132 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Anxiety Scale</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 0-48 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale-15</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 0-15 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 9-56 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 0-28 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire-8</measure>
    <time_frame>Change from baseline to weeks 12 and 24.</time_frame>
    <description>Score range 0-32 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Change from screening to week 24</time_frame>
    <description>Score range 0-30 with higher values indicating more severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Lithium aspartate 15mg a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of elemental lithium administered every morning by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium aspartate 45mg a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg every morning and 25mg every evening of elemental lithium administered by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No lithium treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Lithium aspartate of lithium carbonate will be administered by mouth.</description>
    <arm_group_label>Lithium aspartate 15mg a day</arm_group_label>
    <arm_group_label>Lithium aspartate 45mg a day</arm_group_label>
    <arm_group_label>Lithium carbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Diagnosed with PD according to the UK Brain Bank Criteria.

          2. 45-80yo.

          3. Clinical Dementia Rating Scale score of 0 or 0.5.

          4. Stable PD medications for previous 30 days and no current need for changes in the
             opinion of the PI.

          5. No formed visual hallucinations or delusions for previous year.

          6. Never taken prescription or over-the-counter lithium.

          7. Stable or no diuretics for past 4 weeks and no need for changes for at least 6 months,
             in the PI's opinion.

          8. Stable doses of antidepressants, antihypertensives and non-steroidal anti-inflammatory
             medications (NSAIDs) for previous 60 days and no current need to adjust such
             medications.

          9. No history of cardiac arrhythmias besides atrial fibrillation that is rate controlled.

         10. No unstable cardiac, medical or psychiatric condition in the opinion of the PI.

         11. No current use of illicit drugs or current alcohol abuse in the opinion of the PI.

         12. No history of hypothyroidism, not receiving thyroid replacement therapy and normal
             thyroid stimulating hormone (TSH) level at screening visit.

         13. Estimated renal glomerular filtration rate â‰¥50 at screening visit.

         14. No history of receiving or planning to receive nilotinib or a glucagon-like peptide-1
             agonist medication such as exenatide.

         15. No use of tobacco products for the previous year.

         16. No deep brain stimulation (DBS) or possible need for DBS for at least 1-year in the
             opinion of the PI.

         17. Women with child bearing potential will need a negative pregnancy test and not be
             nursing an infant at screening. Women with child bearing potential will need to report
             using barrier method or hormonal contraception.

         18. Not enrolled in another clinical trial.

         19. Willing and able to sign informed consent and follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Guttuso, MD</last_name>
    <phone>7169326080</phone>
    <email>tguttuso@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Shepherd, RN</last_name>
    <phone>7169326080</phone>
    <email>rlaporta@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Shepherd, RN</last_name>
      <phone>716-932-6080</phone>
      <email>rlaporta@buffalo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Thomas Guttuso</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Lithium</keyword>
  <keyword>Alpha-synuclein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

